Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors (Theresa Study)

NCT03741088 is registered in ClinicalTrials.gov with HistoSonics, Inc. as lead sponsor.

NCT NCT03741088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03741088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors (Theresa Study)
Lead sponsor
HistoSonics, Inc.
Phase
Not applicable
Overall status
Completed
Start date
March 21, 2018
Completion date
July 17, 2019
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, liver metastases